Marrow protection with trilaciclib for advanced solid tumors
Treatments studied
Part of Cancer, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy. It is for people with several types of advanced solid tumors who will receive a specific chemo combination (paclitaxel plus carboplatin) for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and your doctor has rated your daily activity level as 0 (fully active) or 1 (able to do light work).
- You have one of these advanced cancers: non-small cell lung cancer, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, or head and neck cancer.
- You have had no more than one prior chemotherapy regimen, and you have never had paclitaxel plus carboplatin together.
- Your blood counts (red cells, white cells, platelets) and liver/kidney function are within a certain range (your doctor will check).
- You have a tumor that can be measured on scans (like CT or MRI).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve outcomes in people with advanced triple-negative breast cancer who have already tried at least two other chemotherapies.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
This trial tests a drug called trilaciclib, given before chemotherapy to protect your bone marrow (where blood cells are made). It is for people with advanced bile duct or pancreatic cancer who are about to start chemotherapy.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.